Nelson Advisors: The Exit Drought - How Dividend Recaps Are Reshaping Healthcare and HealthTech
Private equity has a liquidity problem, and it is quietly changing how healthcare and healthcare technology companies are financed.
For most of the last decade, the PE playbook was simple. Buy a company, grow it, improve margins, and sell it within five or six years, either to a strategic buyer or to public investors through an IPO. The proceeds flowed back to limited partners (pension funds, endowments, insurers and sovereign wealth funds), who recycled them into the next fund.
That cycle has stalled. IPO windows have been muted, and strategic buyers face a far higher cost of capital than they did before the last rate-hiking cycle. The result is a growing backlog of mature portfolio companies with nowhere to go.
Sponsors still have to return cash to investors, so they are turning to the debt markets. The dividend recapitalisation, or “dividend recap”, has gone from an occasional tactic to a mainstream exit substitute. In healthcare and healthtech, the stakes are unusually high.
What a dividend recap actually is
In a dividend recap, a portfolio company borrows new debt, often through a refinancing or an add-on to existing term loans, and uses the proceeds to pay a special dividend to its private equity owner. The sponsor passes the cash on to its fund investors. No one has sold the company, but money has left it.
The attraction is obvious. Distributions are the metric limited partners care about most right now. A fund that has returned capital looks healthier than one holding unrealised paper gains, and a recap lets a sponsor demonstrate real cash returns without selling a good asset into a weak market. It also keeps the sponsor in control of a company it believes is still undervalued.
The cost is that the company now carries more debt, and it has paid its owners a sum it did not generate in that year. The business gets nothing from the transaction except a heavier interest bill.
The numbers behind the shift
Recent analysis from Moody’s captures the scale of the squeeze. Citing PitchBook data, it notes that private equity distributions have fallen from more than 30% of starting net asset value in 2022 to about 12% today. That is a collapse in the rate at which investors are getting their money back.
Moody’s analyst Mayank Mallik puts the cause bluntly: exits are “few and far between”. European IPO markets have been quiet, and the capital that would normally fund large corporate acquisitions has become much more expensive.
Two other points from the analysis matter for this discussion.
First, the practice remains limited to the strongest performers. Moody’s says sponsors have been “disciplined”, and most recaps involve companies that have outperformed their original business plans, with new debt generally returning leverage to its starting level rather than pushing it materially higher. That is reassuring up to a point. But Moody’s also says this “significant re-leveraging capacity” could support a further ramp-up in recaps, so the practice could spread.
Second, recaps do not solve the underlying problem. Funds are holding assets well beyond the typical five-to-six-year window, and a dividend only returns part of the capital. The exit backlog remains.
Moody’s also flags a subtle trade-off.
Companies preparing for an IPO like to show a couple of years of steady deleveraging first. A business that has just recapitalised may struggle to move quickly if the IPO window suddenly reopens. Any sponsor doing a recap is, in effect, betting that the window stays shut for now.
Why healthcare is a prime candidate
Moody’s lists services, consumer products and manufacturing as the most active sectors, but healthcare has several traits that make it attractive to lenders and sponsors alike.
Defensive demand. People need medical care, medicines and diagnostics whatever the economic cycle. Lenders prize that stability, and it supports higher leverage than a cyclical business could carry.
Predictable cash flow. Many healthcare services run on recurring patient volumes and contracted reimbursement. Many healthtech vendors sell subscription software to hospitals and payers on multi-year contracts. Predictable revenue is exactly what credit investors want to underwrite.
Heavy PE ownership. Private equity has spent years buying and consolidating physician practices, dental and veterinary groups, dermatology and ophthalmology networks, behavioural health providers, home care agencies and diagnostic labs. A large share of the sector’s mid-sized businesses is therefore owned by funds now ageing into the exit backlog.
Roll-up economics. Many of these companies were built through serial acquisitions. Bolt-on deals buy earnings at low multiples and fold them into a larger platform that is valued at a higher one. That model creates a lot of adjusted EBITDA, which is the base lenders use to size new debt.
Taken together, healthcare is exactly the kind of sector where a recap looks defensible: stable, cash-generative and well understood by credit markets.
The risks specific to healthcare
The same features that make healthcare attractive to lenders also make over-leverage unusually risky.
Reimbursement is not in the company’s control. A manufacturer can raise prices. A physician group or a home health agency generally cannot. Revenue depends on payer rates set by governments and insurers, and a rate cut or a change in coverage rules can hit margins overnight. Debt service is fixed, so a business that has just taken on more debt has less room to absorb that kind of shock.
Labour is the biggest cost, and it has been rising. Clinicians, nurses and technicians are in short supply in many markets. Wage inflation has been a persistent pressure, and it is hard to offset with efficiency gains in a business built on human care.
Floating-rate debt bites. Much of the debt in leveraged buyouts is floating-rate. If rates stay elevated, interest costs consume a large share of operating cash flow. A recap that returns leverage to its starting level may look neutral on a ratio basis but still be heavier in cash terms than the original structure was when rates were lower.
Regulatory and political scrutiny. Private equity ownership of healthcare has attracted attention from regulators and legislators in several countries, including questions about whether financial engineering compromises patient care. A company that pays out a large dividend and then runs into financial or quality trouble becomes a ready-made case study for critics.
Operational capacity can get squeezed. When cash flow is committed to servicing debt, there is less left for investment in staff, equipment, facilities and clinical quality. In a sector where quality is the product, that is not a trivial concern.
These are not reasons to conclude that recaps are reckless. Disciplined sponsors will lever the strongest assets, and many healthcare businesses can comfortably support the debt. But the downside scenarios are less forgiving than they are in many other sectors.
Healthcare technology: a different risk profile
Healthtech deserves separate treatment because its financing dynamics look more like software than like healthcare services.
Software style valuations and debt. Revenue cycle management, electronic health records, clinical workflow tools, population health analytics and payer software are often sold on subscription contracts with high retention. Lenders, including a growing private credit sector, are willing to lend against recurring revenue, sometimes on a multiple of annual recurring revenue instead of on traditional cash flow.
The private credit factor. A lot of this lending now comes from private credit funds rather than syndicated bank markets. That makes recaps faster and more flexible to arrange, but it also means the debt can be more expensive and carry features such as payment-in-kind (PIK) interest, where interest accrues to the principal instead of being paid in cash. PIK can ease near-term pressure while enlarging the debt burden later.
Growth versus payout. Healthtech companies are often still investing heavily in product, AI capabilities and integration. A dividend recap takes cash and debt capacity that might otherwise fund that investment. In a fast-moving technology field, that matters. A competitor with a cleaner balance sheet can out-invest a company servicing a recap.
Exit routes are especially narrow. Many healthtech companies would traditionally have been IPO candidates or targets for large strategic acquirers such as big technology firms, payers and large healthcare services groups. With listing markets muted and strategic buyers’ capital more expensive, mature healthtech assets are exactly the kind of company waiting in the exit queue.
Valuation reset hangs over it. Many healthtech businesses were bought or recapitalised at valuations set in a different rate environment. A recap lets a sponsor realise some value without having to mark the asset to today’s market, but if a sale eventually happens at a lower multiple, the extra debt will have eaten into the equity cushion.
Who benefits and who bears the risk?
It helps to think of the different parties.
Sponsors and their investors benefit most clearly. They get cash back, show distributions, and keep ownership of an asset they believe will be worth more later.
Lenders are paid to take the risk, typically through attractive spreads and fees. Moody’s emphasis on discipline suggests they are being selective, but the competitive pressure to deploy capital can erode that discipline over time.
Company management gets stability and continued backing from the sponsor, but also faces a more constrained balance sheet and pressure to hit financial targets.
Employees, patients and customers are the least visible stakeholders. They are not parties to the transaction, but they live with its consequences: staffing levels, investment in facilities, pricing and the pace of product development.
Wider credit markets also bear a share. Moody’s says its interest is in how the private equity ecosystem affects corporate credit quality, and dividend recaps are one of the main transmission mechanisms. A wave of leveraged healthcare issuers carrying more debt than their original plans assumed could eventually show up in defaults and downgrades.
What to watch
For anyone following this market, whether as an investor, an operator, an adviser or a policymaker, a few indicators are worth tracking.
Recap volume in healthcare relative to other sectors. If healthcare moves from a minor part of recap activity to a leading one, it signals that sponsors see it as the most financeable corner of their portfolios.
The quality of the borrowers. Moody’s describes the current cohort as outperformers. A shift toward weaker credits using recaps as a way to ease investor pressure would be a warning sign.
Leverage versus interest cover. Watch not only debt-to-EBITDA but how comfortably earnings cover interest, especially for floating-rate borrowers.
Use of PIK and other structural features. Rising use of payment-in-kind interest would suggest companies are struggling to service debt in cash.
The reopening of the IPO window. If listings return, recapitalised issuers may find their flexibility limited, as Moody’s notes. That would test the sponsors’ bet that the window would stay closed.
Reimbursement and labour-cost trends. These are the operating variables most likely to determine whether healthcare services borrowers can carry what they have taken on.
Regulatory attention. Any move to restrict or scrutinise leveraged payouts from healthcare companies would change the calculus quickly.
The bottom line
The dividend recap is a rational response to a stuck market. With exits scarce and distributions down sharply from their 2022 peak, sponsors are using the debt markets to return cash while they wait. Healthcare and healthtech are natural places to do it, because lenders value their predictable revenue and sponsors own so many mature assets in the sector.
But a rational response for a fund is not automatically a good outcome for the company. In healthcare services, extra leverage sits uncomfortably alongside fixed reimbursement, tight labour markets and high interest rates. In healthtech, it can drain resources from the product investment that sustains competitiveness. And in both, it merely delays a reckoning that the exit backlog will eventually force: assets will have to be sold, at prices the market is willing to pay, to buyers with capital to deploy.
The good news is that, for now, recaps appear to be concentrated in the strongest companies and are generally restoring leverage to original levels rather than breaking new ground. The risk is that success breeds imitation. If the exit drought continues and the practice spreads beyond the best performers, today’s careful releveraging could become tomorrow’s credit problem, and in healthcare, where the product is care for people, the consequences would reach well beyond the balance sheet.
Sources: Moody’s, CNBC, PitchBook data on private equity distributions.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Healthcare.Digital serves as a research platform for Nelson Advisors’ perspectives on deals, valuations and structural shifts reshaping Global Digital Health, MedTech, Healthcare AI and Health IT. https://www.healthcare.digital
Nelson Advisors is one of Europe's leading mergers and acquisitions advisory firms, exclusively dedicated to the dynamic and rapidly evolving healthcare technology sector. With a deep understanding of market dynamics and technological advancements, they empower innovative HealthTech companies and strategic investors to navigate complex transactions and achieve their growth ambitions. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #Genomics
Nelson Advisors
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments